<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>
<channel>
	<title>Medical Product Guide&#187; Lamictal XR</title>
	<atom:link href="http://blog.medicalproductguide.com/tag/lamictal-xr/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.medicalproductguide.com</link>
	<description>A comprehensive guide to medical products for medical professionals</description>
	<lastBuildDate>Mon, 20 Jun 2011 12:36:09 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.3</generator>
		<item>
		<title>GlaxoSmithKline Receives Okay From FDA For Lamictal</title>
		<link>http://blog.medicalproductguide.com/2010/02/02/glaxosmithkline-recieves-fda-lamictal/</link>
		<comments>http://blog.medicalproductguide.com/2010/02/02/glaxosmithkline-recieves-fda-lamictal/#comments</comments>
		<pubDate>Tue, 02 Feb 2010 04:54:26 +0000</pubDate>
		<dc:creator>Jim Marino</dc:creator>
				<category><![CDATA[FDA approvals]]></category>
		<category><![CDATA[epilepsy]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[Lamictal XR]]></category>
		<category><![CDATA[partial onset seizures]]></category>
		<category><![CDATA[primary generalized tonic-clonic seizures]]></category>
		<guid isPermaLink="false">http://www.medicalproductguide.com/blog/?p=423</guid>
		<description><![CDATA[The FDA has approved GlaxoSmithKline’s Lamictal XR extended-release tablets as once-a-day, add-on therapy for epilepsy in patients over 13 years of age suffering from primary generalized tonic-clonic seizures. Lamictal XR is already approved for partial onset seizures for patients in this age group. The study depicted that the addition of Lamictal XR in therapy reduced [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://blog.medicalproductguide.com/files/2010/02/Glaxo.png"><img class="alignright size-full wp-image-424" style="margin: 5px" src="http://blog.medicalproductguide.com/files/2010/02/Glaxo.png" alt="Glaxo" width="200" height="64" /></a>The FDA has approved GlaxoSmithKline’s Lamictal XR extended-release tablets as once-a-day, add-on therapy for epilepsy in patients over 13 years of age suffering from primary generalized tonic-clonic seizures. Lamictal XR is already approved for partial onset seizures for patients in this age group.</p>
<p>The study depicted that the addition of Lamictal XR in therapy reduced the seizure frequency more than placebo in patients with uncontrolled primary generalized tonic-clonic seizures.</p>
]]></content:encoded>
			<wfw:commentRss>http://blog.medicalproductguide.com/2010/02/02/glaxosmithkline-recieves-fda-lamictal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Served from: blog.medicalproductguide.com @ 2012-02-07 11:21:19 -->
